Bill SlivkaBusiness Strategy and Commercialization
Bill is a seasoned manager with over 30 years in the consumer health industry. He has deep experience in classic brand marketing, Rx-to-OTC switch, and new business acquisition and commercialization, both US and global.
From 1996 to 2010, Bill held a range of senior leadership positions with GlaxoSmithKline Consumer Healthcare, including serving as VP and head of the global smoking control business, the global analgesics business, and the U.S. smoking control business. As head of the global smoking cessation category unit, Bill led the roll-out of GSK's smoking control products into a dozen European, Asian and Latin American countries. Earlier, in the U.S., Bill was responsible for the growth of GSK's best-selling family of smoking control brands, Nicorette Gum, NicoDerm Patches and Commit Lozenges, utilizing innovative marketing and public health-driven strategies.
Most recently, Bill was VP and commercial head of GSK Consumer Healthcare's Venture Group, charged with identifying and building the business case for introducing and rapidly commercializing new technologies in the consumer health space. He also led the North America Strategy Team, responsible for long term planning and allocation of investment.
Prior to GSK, Bill spent 18 years at several Johnson & Johnson companies in classic marketing roles. His final two assignments included driving the commercial aspects of the J&J Merck partnership start-up and leading J&J's global baby and wound care franchises.
Bill holds a BA degree from Harvard College and an MBA from Harvard Business School. In addition to supporting NCI clients, Bill serves as Executive-in-Residence at the University of Pittsburgh Joseph M, Katz Graduate School of Business.